10-Q: Cogent Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update

Sentiment:

Quarterly Report 6 May 2025 9:00 AM

📋All filings for Cogent Biosciences, INC

Cogent Biosciences reports a net loss for Q1 2025 and provides updates on its clinical programs, including expected top-line results and NDA submission plans.

Summary

Cogent Biosciences, a clinical-stage biotechnology company, reported its financial results for the first quarter of 2025.
The company's net loss for the quarter was $72.0 million, compared to a net loss of $58.3 million for the same period in 2024.
Research and development expenses increased to $63.0 million from $52.7 million year-over-year.
General and administrative expenses also rose to $11.9 million from $9.7 million in the prior year.
As of March 31, 2025, Cogent had cash, cash equivalents, and marketable securities totaling $245.7 million.
The company anticipates that its current financial resources will be sufficient to fund operations through clinical readouts from ongoing trials and into late 2026.
Cogent expects to report top-line results from the SUMMIT trial in July 2025 and from the APEX trial in the second half of 2025.
The company plans to submit the first bezuclastinib New Drug Application (NDA) by the end of 2025 for patients with Systemic Mastocytosis (SM).

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company reported a net loss, it has sufficient cash to fund operations through late 2026 and is progressing its clinical programs with expected top-line results and NDA submission plans. The company is also advancing its research programs and has initiated expanded access programs for SM and GIST patients.

Positives

Cogent Biosciences has $245.7 million in cash, cash equivalents, and marketable securities, expected to fund operations through clinical readouts and into late 2026.
The company is on track to submit an NDA for bezuclastinib by the end of 2025.
The company has completed enrollment in APEX Part 2 with 58 patients.
The company has initiated expanded access programs for SM and GIST patients.
The company has presented updated positive clinical data from the lead-in portion of the PEAK trial at the 2024 American Society of Clinical Oncology meeting.
The company has presented robust tumor growth inhibition in a mutant Her2-YVMA subcutaneous Patient Derived Xenograft model, supporting potential clinical development in HER2-YVMA lung cancer.
CGT6297 has been selected as our clinical candidate for the PI3K 1047 mutation focused project.

Negatives

Cogent Biosciences reported a net loss of $72.0 million for the first quarter of 2025, an increase from $58.3 million in the same period last year.
The company has incurred significant operating losses since inception and expects to continue to do so for the next several years.
The company does not have any products approved for sale and has not generated any revenue from product sales.

Risks

The company's ability to generate product revenue and achieve profitability depends on the successful development and commercialization of its product candidates.
The company may be unable to raise additional funds or enter into agreements on favorable terms, or at all.
If the company fails to raise capital or enter into agreements, it may have to delay, scale back, or discontinue the development and commercialization of its product candidates.
The successful development and commercialization of the company's product candidates is highly uncertain due to numerous risks and uncertainties associated with product development and commercialization.
The company's utilization of net operating loss carryforwards and tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986.

Future Outlook

Cogent Biosciences expects its current cash, cash equivalents, and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements through clinical readouts from ongoing SUMMIT, PEAK, and APEX registration-directed trials and into late 2026. The company plans to submit the first bezuclastinib New Drug Application (NDA) by the end of 2025 for patients with SM.

Management Comments

Based on our current plans, we believe that our existing cash, cash equivalents and marketable securities of $245.7 million as of March 31, 2025 will enable us to fund our operating expenses and capital expenditure requirements through clinical readouts from ongoing SUMMIT, PEAK, and APEX registration-directed trials and into late 2026.

Industry Context

Cogent Biosciences is focused on developing precision therapies for genetically defined diseases, aligning with the broader industry trend towards targeted treatments and personalized medicine. The company's focus on specific mutations in KIT, FGFR2, ErbB2, PI3K and KRAS reflects a growing understanding of the genetic drivers of cancer and other diseases, and the potential for more effective and less toxic therapies.

Comparison to Industry Standards

The median progression-free survival (mPFS) on the combination of bezuclastinib and sunitinib was 10.2 months in all patients in the lead-in portion of the PEAK trial, this is comparable to other second-line GIST treatments.
In a subset of second-line GIST patients with only prior imatinib, the data demonstrate a mPFS of 19.4 months, this is a strong result compared to sunitinib monotherapy.
The company's research team is also advancing a novel, ErbB2 mutant program, which is focused on actionable and underserved mutations in a variety of solid tumor indications, and demonstrates advantages versus tucatinib, an approved benchmark compound, on tumor growth inhibition in a peripheral ErbB2 L755S driven mutant model, as well as in an ErbB2 driven intracranial model.

Legal Proceedings

The Company is not currently party to any material legal proceedings.

Stakeholder Impact

Shareholders: Dilution may occur if additional equity is raised.
Employees: Continued employment is dependent on the company's financial stability and progress.
Patients: Potential for new treatment options for genetically defined diseases.
Creditors: Repayment of debt is dependent on the company's financial performance.

Next Steps

Report top-line results from the SUMMIT trial in July 2025.
Report top-line results from the APEX trial in the second half of 2025.
Submit the first bezuclastinib New Drug Application (NDA) by the end of 2025 for patients with SM.
Continue enrollment in the Phase 1 study of CGT4859 in patients with tumors bearing FGFR2 and FGFR3 mutations.
Submit an IND application for the ErbB2 clinical candidate in 2025.
Initiate IND-enabling studies for the PI3K 1047 mutation focused project and expect to submit an IND application in 2025.
Continue lead optimization of the CGT9109 series.

Key Dates

Date	Description
July 6, 2020	Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock with the Secretary of State of the State of Delaware.
October 22, 2020	The board of directors adopted the Cogent Biosciences, Inc. 2020 Inducement Plan.
May 6, 2022	The Company entered into a Sales Agreement with Guggenheim Securities, LLC.
June 2022	Payment of $2.5 million to Plexxikon due to the progression of the PEAK study.
February 10, 2023	The Company filed a Form S-3ASR with the SEC (2023 Shelf Registration).
April 2023	Initiated Part 2 of the APEX trial using the optimized formulation of bezuclastinib at 150 mg daily dose.
June 7, 2023	Stockholders approved the 2023 Pool Increase and a grant date was established for accounting purposes for these PSUs in accordance with ASC 718 CompensationStock Compensation.
February 13, 2024	The Company entered into a Securities Purchase Agreement for a private placement.
February 14, 2024	The Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series B Non-Voting Convertible Preferred Stock with the Secretary of State of the State of Delaware.
March 21, 2024	The Company entered into exchange agreements with certain of the Purchasers.
June 5, 2024	At the Companys 2024 annual meeting of stockholders, the Companys stockholders approved an amendment to the Companys Third Amended and Restated Certificate of Incorporation.
June 10, 2024	13,712 shares of Series B Preferred Stock automatically converted to 13,712,000 shares of common stock.
May 6, 2025	We filed with the SEC (a) a post-effective amendment to the 2022 Registration Statement terminating the offering of the Unsold Securities under the 2022 Registration Statement, and (b) a prospectus supplement to our automatic shelf registration statement on Form S-3ASR (Registration No. 333-269707), which registration statement was filed and became effective on February 10, 2023 (the 2023 Registration Statement), to register the offering of the Unsold Securities under the 2023 Registration Statement.
July 2025 (Expected)	Expected top-line results from the SUMMIT trial.
Second Half 2025 (Expected)	Expected top-line results from the APEX trial.
End of 2025 (Planned)	Planned submission of the first bezuclastinib New Drug Application (NDA).

Keywords

bezuclastinib, systemic mastocytosis, GIST, clinical trials, NDA, CGT4859, FGFR2, ErbB2, PI3K, KRAS, financial results, Cogent Biosciences

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.